PPi - Pharmaprice International
 
 
 
 
Locations

Argentina
Asia region
Australia

Austria
Brazil
Canada

Cyprus
Egypt
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Netherlands
Portugal
Spain
Sweden
Turkey
United Kingdom
USA

PPi - Your experts in Pricing, Reimbursement and Market Access

Case Studies

Product Launch Sequence
Due Diligence Assessment for 2 agents
European Pricing and Reimbursement (P&R) Planning
European Patent Expiry Planning
Product Pricing and Reimbursement Strategy & Assessment of Client Structure and Processes
International Reimbursement Planning
Pricing and Reimbursement Implementation
Pricing and Reimbursement Strategy and Launch Planning

 

Product Launch Sequence


Objectives

To recommend the ideal launch sequence (to optimise commercial opportunity and maintain achievable price levels) for 3 separate products

Therapy Area

Renal

Client

German pharmaceutical company

Product/Technology

Drugs

Scope

36 countries across Western and Eastern Europe, Middle East and Northern and South Africa

PPi Workplan

Modelled optimal launce sequences using PPi External Reference Price (ERP) Database and price and forecast data from client

Project Duration
8 days

Outcome
Ideal launch sequence and rationale provided for each of the 3 products, including details of how ERP affects each country.


Back to top

 
Due Diligence Assessment for 2 agents

Objectives
To assess the prospective pricing and reimbursement (P&R) environment for 2 novel formulation drugs to support client’s decision whether to in-licence the products.

Therapy Area
GI

Client
UK pharmaceutical company

Product/Technology
Drugs

Scope
UK, Germany, France, Spain, Italy and Netherlands

PPi Workplan
Compared agents with appropriate comparator agents and P&R proxies for novel formulation drugs and considered relevant state P&R regulations

Project Duration
13 days

Outcome
Analysis recommended favourable P&R environment for both agents and advocated proceeding with in-licence. Also guidance provided for necessary clinical programmes and data needs to achieve optimal P&R.


Back to top

 
European Pricing and Reimbursement (P&R) Planning


Objectives
To advise on such as clinical programme, reimbursement needs, market access, representational and distribution issues for new technology

Therapy Area
Oncology

Client
USA device company

Product/Technology
Device incorporating stem cell technology

Scope
UK, Germany, France, Italy, Spain, Netherlands

PPi Workplan
Consulted with appropriate in-market stakeholders (clinicians, regulators, payers, pharmacists, logistics) to assess respective issues and provide recommendations

Project Duration
12 weeks

Outcome
Guidance provided on all pertinent issues including on clinical programme design and appropriate QoL instrument for clinical study, DRG (diagnosis related groups) issues and actions, price guidance, specific reimbursement processes and activities and suggested in-market prelaunch activities.


Back to top

 
European Patent Expiry Planning


Objectives
To assess European sales impact of lowering price of brand in selective countries where patent soon expiring

Therapy Area
Arthritis

Client
Spanish pharmaceutical company

Product/Technology
Drug

Scope
UK, Germany, France, Italy, Spain, Netherlands, Belgium, Portugal, Greece

PPi Workplan
Modelled likely impacts of price reductions using PPi External Reference Price (ERP) Database and PPi Parallel Trade Model, in various scenarios based on client forecast data

Project Duration
15 days

Outcome
Modelled 4 different scenarios and presented summarised overall findings including revenue impact of adopting different pricing scenarios and PPi’s recommended approach.


Back to top

 
Product Pricing and Reimbursement Strategy & Assessment of Client Structure and Processes


Objectives
Developing the P&R strategy for 2 products as case studies to help review current P&R practice and processes within the client with a view to establishing improved and earlier decision-making

Therapy Area
Neurology & Haematology

Client
UK diagnostics company

Product/Technology
Diagnostics

Scope
USA, UK, Germany, France, Italy, Spain

PPi Workplan
Discussions with internal staff in marketing and other functions supplemented by in-market discussions with payers and hospital staff with analysis drawn from both aspects

Project Duration
5 months

Outcome
Recommendations provided on P&R strategy and necessary market access activities for each product as well as on an improved, integrated structure and decision process for development products


Back to top

 
International Reimbursement Planning


Objectives
To establish data needs and activities required to achieve reimbursement and market access

Therapy Area
Allergy

Client
Danish pharmaceutical company

Product/Technology
Vaccine

Scope
11 European countries

PPi Workplan
Development of product profile and discussion template followed by fieldwork discussions in each market and analysis of issues

Project Duration
16 weeks

Outcome
119 page report and summary presentation provided of PPi’s findings and recommendations including health economic requirements, reimbursement issues, necessary clinical data and in-market pre-launch activity plan.


Back to top

 
Pricing and Reimbursement Implementation


Objectives
To secure P&R in selective territories where the client had no affiliate/entity

Therapy Area
Epilepsy

Product/Technology
Drug

Scope
Benelux, Greece, Portugal, Hungary, Czech Republic and Poland

PPi Workplan
PPi developed submission and appropriate supportive materials and then liaised with appropriate State Authority to submit and secure P&R

Project Duration
6 months+

Outcome
P&R achieved in the designated territories with market access strategies developed for those countries where the desired P&R were difficult to achieve.


Back to top

 
Pricing and Reimbursement Strategy and Launch Planning


Objectives
To develop P&R strategy, assess pre-approval use possibilities and identify any specific local issues

Therapy Area
Orphan inherited disease

Client
USA Biopharmaceutical company

Product/Technology
Drug

Scope
15 European countries

PPi Workplan
PPi developed product profile and discussion guide followed by Key Opinion Leader (KOL) and payer discussions in each territory

Project Duration
12 weeks

Outcome
Provided 118 page report and a summary presentation of findings and recommendations including in-market and international pricing strategy, optimal launch sequence, reimbursement data needs, identifying main likely treatment centres and markets where a pre-approval use availability was advocated.

 
 
 
PharmaPriceinternational     PharmaPriceinternational     pharmapriceinternational     PharmaPriceinternational
 
 
© 2011 PharmaPrice International Ltd
Tel: +44 (0)2380 847891    Email:
info@pharmaprice.net